Repligen (RGEN) Capital Expenditures Growth (1y) (2011 - 2026)
Powered by 
Analysis
Repligen (RGEN) Capital Expenditures Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 241.68 Bn | 237.61 Bn | 8.34 Bn | 53.06% |
| 2 | Danaher | 147.34 Bn | 142.99 Bn | 3.61 Bn | 8.47% |
| 3 | Agilent Technologies | 43.34 Bn | 41.59 Bn | 1.04 Bn | -22.33% |
| 4 | Illumina | 34.58 Bn | 33.41 Bn | 770.00 Mn | 33.33% |
| 5 | Revvity | 16.31 Bn | 15.29 Bn | 416.87 Mn | -41.31% |
| 6 | Bio-Techne | 11.28 Bn | 11.01 Bn | 211.39 Mn | 73.42% |
| 7 | Bio-Rad Laboratories | 10.16 Bn | 8.54 Bn | 345.80 Mn | -29.98% |
| 8 | Repligen | 9.77 Bn | 8.75 Bn | 110.04 Mn | -24.88% |
| 9 | 10x Genomics | 9.45 Bn | 8.90 Bn | 112.50 Mn | 0.63% |
| 10 | Bruker | 9.26 Bn | 9.04 Bn | 416.00 Mn | 35.21% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.88% |
| Mar 31, 2026 | 32.19% |
| Dec 31, 2025 | 47.17% |
| Sep 30, 2025 | -32.67% |
| Jun 30, 2025 | 47.69% |
| Mar 31, 2025 | -57.31% |
| Dec 31, 2024 | -50.03% |
| Sep 30, 2024 | -16.73% |
| Jun 30, 2024 | -41.65% |
| Mar 31, 2024 | -1.92% |
| Dec 31, 2023 | -45.77% |
| Sep 30, 2023 | -29.02% |
| Jun 30, 2023 | -67.52% |
| Mar 31, 2023 | -68.72% |
| Dec 31, 2022 | -36.35% |
| Sep 30, 2022 | 8.47% |
| Jun 30, 2022 | 53.83% |
| Mar 31, 2022 | 258.70% |
| Dec 31, 2021 | 182.05% |
| Sep 30, 2021 | 188.43% |